ATHIRA PHARMA INC (ATHA) Stock News
NASDAQ:ATHA - Nasdaq - US04746L1044 - Common Stock - Currency: USD
ATHA Latest News, Press Relases and Analysis
Ascendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long Term
We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where Ascendis Pharma A/S (NASDAQ:ASND) stands against the other growth stocks. What’s the Bull Case for US Equities? The market closed last week mostly lower, however, […]
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics...
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Athira Pharma (NASDAQ:ATHA) just reported results for the second quarter of 202...
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer...
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing...
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing...
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the second quarter of 2024.
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected...
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
On Wednesday, Athira Pharma, Inc. (NASDAQ:ATHA) stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer’s disease (AD). A -0.08 change in GST (the Global Statistical Test, a combination of results from measures of cognition (ADAS-Cog11) and function (ADCS-ADL23) favoring fosgonimeton that did not reach statistical significance (p=0.70) The change in cognition from baseline, for which a decrease fro
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified...
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates ...
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau...
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients...
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)...